Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial
| Autor: | Ignacio J, Amat-Santos, Juan P, Sánchez-Luna, Emad, Abu-Assi, María, Melendo-Viu, Ignacio, Cruz-Gonzalez, Luis, Nombela-Franco, Antonio J, Muñoz-Garcí, Sergio G, Blas, Jose M, de la Torre Hernandez, Rafael, Romaguera, Ángel, Sánchez-Recalde, José L, Diez-Gil, Diego, Lopez-Otero, Livia, Gheorge, Borja, Ibáñez, Andrés, Iñiguez-Romo, Sergio, Raposeiras-Roubín, Fernando, Alfonso |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Transcatheter aortic Ventricular Function Left law.invention Transcatheter Aortic Valve Replacement chemistry.chemical_compound Randomized controlled trial Glucosides law Internal medicine Diabetes mellitus medicine Humans Prospective Studies Dapagliflozin Benzhydryl Compounds Heart Failure Ejection fraction business.industry Stroke Volume Aortic Valve Stenosis medicine.disease Stenosis Treatment Outcome chemistry Heart failure Aortic Valve Cardiology Cardiology and Cardiovascular Medicine business Kidney disease |
| Zdroj: | European journal of heart failureReferences. 24(3) |
| ISSN: | 1879-0844 |
| Popis: | Aims Despite aortic stenosis (AS) relief, patients undergoing transcatheter aortic valve implantation (TAVI) are at increased risk of developing heart failure (HF) within first months of intervention. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have been shown to reduce the risk of HF hospitalization in individuals with diabetes mellitus (DM), reduced left ventricular ejection fraction (LVEF) and chronic kidney disease (CKD). However, the effect of SGLT-2 inhibitors on outcomes after TAVI is unknown. The Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) trial is designed to assess the clinical benefit and safety of the SGLT-2 inhibitor dapagliflozin in patients undergoing TAVI. Methods DapaTAVI is an independent pragmatic, controlled, prospective, randomized, open-label blinded end-point, multi-center trial conducted in Spain, evaluating the effect of dapagliflozin 10 mg/day on the risk of death and worsening HF in patients with severe AS undergoing a TAVI. Candidate patients should have prior history of HF admission plus ≥1 of the following criteria: 1) DM, 2) LVEF ≤40%, or 3) estimated glomerular filtrate rate between 25 and 75 mL/min/1.73 m2. A total of 1020 patients will be randomized (1:1) to dapagliflozin versus no dapagliflozin. Key secondary outcomes include: (i) Incidence rate of individual components of the primary outcome; (ii) Cardiovascular mortality; (iii) The composite of HF hospitalization or CV death; (iv) Total number of recurrent HF hospitalizations. Conclusion DapaTAVI will determine the efficacy and safety of dapagliflozin in a broad spectrum of frail patients after AS relief by TAVI. This article is protected by copyright. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text